Esther Roe
Overview
Explore the profile of Esther Roe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peirano F, Rusinol L, Iznardo H, Carmona-Rocha E, Puig L, Roe E
Clin Exp Dermatol
. 2025 Jan;
PMID: 39775820
No abstract available.
2.
Iznardo H, Roe E, Vicente A, Prat C, Casals M, Martin-Santiago A, et al.
Clin Exp Dermatol
. 2024 Aug;
50(1):104-112.
PMID: 39093288
Background: Moderate-to-severe atopic dermatitis (AD) can be difficult to manage in paediatric patients, and there are few licensed treatments available for this age group. Dupilumab is approved for the treatment...
3.
Iznardo H, Lopez-Torija I, Mateu-Arrom L, Escribano-Sanz P, Puig L, Roe E
Pediatr Dermatol
. 2024 Jun;
41(5):940-941.
PMID: 38858093
Development of periungual pyogenic granulomas (pPGs) has been associated with several systemic treatments, including retinoids, taxanes, epidermal growth factor receptor inhibitors, and vascular endothelial growth factor inhibitors. We present the...
4.
Iznardo H, Bernal S, Boronat S, Roe E
Pediatr Neurol
. 2023 Aug;
148:14-16.
PMID: 37634327
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder that can involve multiple organ systems. Diagnosis is based on independent clinical diagnostic criteria and genetic diagnostic criteria (pathogenic variants...
5.
Iznardo H, Roe E, Serra-Baldrich E, Puig L
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839707
Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children...
6.
Furlano M, Ars E, Matamala A, Brossa V, Marti J, Del Prado-Venegas M, et al.
Case Rep Genet
. 2023 Jan;
2022:3208810.
PMID: 36619006
Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants of the gene. Heterozygous female patients may show much more variability in clinical manifestations, ranging from...
7.
Gelmetti C, Rigoni C, Cantu A, Agolzer A, Agrusa A, Brena M, et al.
J Dermatolog Treat
. 2022 Oct;
34(1):2131703.
PMID: 36205596
To investigate the efficacy and tolerability of a cream (Rilastil Xerolact PB) containing a mixture of prebiotics and postbiotics, and to validate the PRURISCORE itch scale in the management of...
8.
Amat-Samaranch V, Yelamos O, Agut-Busquet E, Dalmau J, Mozos A, Lopez S, et al.
Australas J Dermatol
. 2022 May;
63(3):e251-e254.
PMID: 35510363
Proliferative nodules (PNs) are benign nodular proliferation of melanocytes occurring within congenital melanocytic naevi (CMN). Differential diagnosis between PN and melanoma is challenging for clinicians and pathologists. We describe the...
9.
Colmenero M, Del Boz J, Bernabeu Wittel J, Roe E, Feito-Rodriguez M, Vicente-Villa M, et al.
Pediatr Dermatol
. 2022 May;
39(4):557-562.
PMID: 35504688
Background: Guidelines and expert recommendations on infantile hemangiomas (IH) are aimed at increasing homogeneity in clinical decisions based on the risk of sequelae. Objective: The objective was to analyze the...
10.
Baselga E, El Hachem M, Diociaiuti A, Carnevale C, Downey C, Roe E, et al.
Eur J Dermatol
. 2022 Feb;
31(6):785-790.
PMID: 35107070
Background: Oral propranolol accelerates the involution of infantile haemangiomas (IHs). However, it is not clear whether IHs treated with oral propranolol are associated with fewer sequelae than when left untreated....